Cobimetinib-induced "dropped head syndrome" and subsequent disease management in an Erdheim-Chester patient

Clin Case Rep. 2019 Sep 10;7(10):1989-1993. doi: 10.1002/ccr3.2297. eCollection 2019 Oct.

Abstract

Our rechallenge of cobimetinib in an Erdheim-Chester Disease (ECD) patient for the rare adverse effect, "dropped head syndrome," with a previously unexplored cobimetinib regimen was successful. Similar to other experiences with targeted agents in ECD, dosing of cobimetinib may vary to mitigate toxicity without impairing efficacy.

Keywords: Erdheim‐Chester disease; hematology; neurology; pharmacology.

Publication types

  • Case Reports